Does the media favor MDXG or IRON?

In the previous week, MiMedx Group had 2 more articles in the media than Disc Medicine. MarketBeat recorded 4 mentions for MiMedx Group and 2 mentions for Disc Medicine. MiMedx Group's average media sentiment score of 0.44 beat Disc Medicine's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MDXG or BEAM?

In the previous week, Beam Therapeutics had 4 more articles in the media than MiMedx Group. MarketBeat recorded 8 mentions for Beam Therapeutics and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.30 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CLDX or MDXG?

In the previous week, Celldex Therapeutics had 1 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for Celldex Therapeutics and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.44 beat Celldex Therapeutics' score of 0.20 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, MDXG or IMNM?

MiMedx Group has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.58 $48.58M $0.04 113.75 Immunome $6.94M 346.47 -$212.39M -$2.53 N/A

Is MDXG or IMNM more profitable?

MiMedx Group has a net margin of 1.76% compared to Immunome's net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% Immunome N/A -50.56% -46.93%

Does the media refer more to MDXG or IMNM?

In the previous week, Immunome had 7 more articles in the media than MiMedx Group. MarketBeat recorded 11 mentions for Immunome and 4 mentions for MiMedx Group. Immunome's average media sentiment score of 0.62 beat MiMedx Group's score of 0.44 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 3 Very Positive mention(s) 6 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or MDXG?

In the previous week, Nurix Therapeutics had 2 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Nurix Therapeutics and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.44 beat Nurix Therapeutics' score of 0.15 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MiMedx Group (MDXG) Competitors

$4.62 +0.07 (+1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$4.61 -0.01 (-0.22%)

As of 07:30 PM Eastern

Compare

MDXG vs. IRON, BEAM, CLDX, IMNM, and NRIX

Should you buy MiMedx Group stock or one of its competitors? MiMedx Group's main competitors and comparable companies include Disc Medicine (IRON), Beam Therapeutics (BEAM), Celldex Therapeutics (CLDX), Immunome (IMNM), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MiMedx Group compare to Disc Medicine?

MiMedx Group (NASDAQ:MDXG) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

MiMedx Group has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.58	$48.58M	$0.04	113.75
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

MiMedx Group currently has a consensus price target of $8.57, suggesting a potential upside of 88.38%. Disc Medicine has a consensus price target of $110.18, suggesting a potential upside of 73.98%. Given MiMedx Group's higher possible upside, equities research analysts clearly believe MiMedx Group is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MiMedx Group had 2 more articles in the media than Disc Medicine. MarketBeat recorded 4 mentions for MiMedx Group and 2 mentions for Disc Medicine. MiMedx Group's average media sentiment score of 0.44 beat Disc Medicine's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Disc Medicine's net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Disc Medicine	N/A	-37.17%	-33.65%

MiMedx Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

MiMedx Group beats Disc Medicine on 11 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to Beam Therapeutics?

MiMedx Group (NASDAQ:MDXG) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

MiMedx Group currently has a consensus target price of $8.57, suggesting a potential upside of 88.38%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 90.88%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

MiMedx Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, meaning that its share price is 120% more volatile than the broader market.

In the previous week, Beam Therapeutics had 4 more articles in the media than MiMedx Group. MarketBeat recorded 8 mentions for Beam Therapeutics and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.30 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Beam Therapeutics' net margin of -54.75%. MiMedx Group's return on equity of 12.09% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MiMedx Group has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.58	$48.58M	$0.04	113.75
Beam Therapeutics	$139.74M	18.97	-$79.99M	-$0.86	N/A

Summary

Beam Therapeutics beats MiMedx Group on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

MiMedx Group has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,661.88	-$258.76M	-$4.35	N/A
MiMedx Group	$418.63M	1.58	$48.58M	$0.04	113.75

Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

79.2% of MiMedx Group shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Celldex Therapeutics had 1 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for Celldex Therapeutics and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.44 beat Celldex Therapeutics' score of 0.20 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Celldex Therapeutics' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
MiMedx Group	1.76%	12.09%	9.22%

Celldex Therapeutics presently has a consensus price target of $61.92, suggesting a potential upside of 90.01%. MiMedx Group has a consensus price target of $8.57, suggesting a potential upside of 88.38%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Celldex Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

MiMedx Group beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Immunome?

MiMedx Group (NASDAQ:MDXG) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

MiMedx Group has a net margin of 1.76% compared to Immunome's net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Immunome	N/A	-50.56%	-46.93%

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiMedx Group presently has a consensus price target of $8.57, suggesting a potential upside of 88.38%. Immunome has a consensus price target of $34.25, suggesting a potential upside of 61.79%. Given MiMedx Group's higher probable upside, research analysts clearly believe MiMedx Group is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Immunome had 7 more articles in the media than MiMedx Group. MarketBeat recorded 11 mentions for Immunome and 4 mentions for MiMedx Group. Immunome's average media sentiment score of 0.62 beat MiMedx Group's score of 0.44 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	3 Very Positive mention(s)	6 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.58	$48.58M	$0.04	113.75
Immunome	$6.94M	346.47	-$212.39M	-$2.53	N/A

MiMedx Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Immunome has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market.

Summary

MiMedx Group beats Immunome on 9 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

MiMedx Group has a net margin of 1.76% compared to Nurix Therapeutics' net margin of -928.44%. MiMedx Group's return on equity of 12.09% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
MiMedx Group	1.76%	12.09%	9.22%

Nurix Therapeutics currently has a consensus price target of $34.21, suggesting a potential upside of 49.54%. MiMedx Group has a consensus price target of $8.57, suggesting a potential upside of 88.38%. Given MiMedx Group's higher probable upside, analysts clearly believe MiMedx Group is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.27	-$264.46M	-$3.45	N/A
MiMedx Group	$418.63M	1.58	$48.58M	$0.04	113.75

In the previous week, Nurix Therapeutics had 2 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Nurix Therapeutics and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.44 beat Nurix Therapeutics' score of 0.15 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.2% of MiMedx Group shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nurix Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Summary

MiMedx Group beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$663.21M	$3.81B	$7.10B	$13.40B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	23.95	13.29	273.96	26.31
Price / Sales	1.61	1,311.95	638.22	101.44
Price / Cash	8.21	39.04	27.22	34.74
Price / Book	2.67	16.78	11.09	6.35
Net Income	$48.58M	-$23.16M	$3.49B	$381.26M
7 Day Performance	-1.07%	-4.05%	-2.30%	-0.61%
1 Month Performance	1.09%	-12.06%	-7.05%	-4.84%
1 Year Performance	-36.80%	14.68%	5.64%	1.12%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	2.3638 of 5 stars	$4.62 +1.5%	$8.57 +85.5%	-36.9%	$663.21M	$418.63M	23.95	808
IRON Disc Medicine	2.2628 of 5 stars	$65.64 +1.1%	$110.18 +67.9%	-6.6%	$2.52B	N/A	N/A	165
BEAM Beam Therapeutics	2.4165 of 5 stars	$24.31 +0.3%	$49.00 +101.6%	-0.3%	$2.51B	$139.74M	N/A	540	Analyst Upgrade Gap Up
CLDX Celldex Therapeutics	2.0459 of 5 stars	$31.49 flat	$61.92 +96.6%	+23.4%	$2.47B	$1.54M	N/A	198
IMNM Immunome	2.8502 of 5 stars	$21.70 +0.1%	$35.18 +62.2%	+71.0%	$2.46B	$6.94M	N/A	177	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. IRON, BEAM, CLDX, IMNM, and NRIX

How does MiMedx Group compare to Disc Medicine?

Summary

How does MiMedx Group compare to Beam Therapeutics?

Summary

How does MiMedx Group compare to Celldex Therapeutics?

Summary

How does MiMedx Group compare to Immunome?

Summary

How does MiMedx Group compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. IRON, BEAM, CLDX, IMNM, and NRIX

How does MiMedx Group compare to Disc Medicine?

Which has stronger earnings and valuation, MDXG or IRON?

Do analysts recommend MDXG or IRON?

Do institutionals and insiders hold more shares of MDXG or IRON?

Does the media favor MDXG or IRON?

Is MDXG or IRON more profitable?

Which has more volatility and risk, MDXG or IRON?

Summary

How does MiMedx Group compare to Beam Therapeutics?

Do analysts prefer MDXG or BEAM?

Which has more volatility & risk, MDXG or BEAM?

Does the media prefer MDXG or BEAM?

Is MDXG or BEAM more profitable?

Do insiders & institutionals hold more shares of MDXG or BEAM?

Which has stronger earnings and valuation, MDXG or BEAM?

Summary

How does MiMedx Group compare to Celldex Therapeutics?

Which has stronger valuation & earnings, CLDX or MDXG?

Which has more risk & volatility, CLDX or MDXG?

Do insiders and institutionals have more ownership in CLDX or MDXG?

Does the media refer more to CLDX or MDXG?

Is CLDX or MDXG more profitable?

Do analysts prefer CLDX or MDXG?

Summary

How does MiMedx Group compare to Immunome?

Is MDXG or IMNM more profitable?

Do institutionals and insiders have more ownership in MDXG or IMNM?

Do analysts prefer MDXG or IMNM?

Does the media refer more to MDXG or IMNM?

Which has higher earnings & valuation, MDXG or IMNM?

Which has more volatility and risk, MDXG or IMNM?

Summary

How does MiMedx Group compare to Nurix Therapeutics?

Is NRIX or MDXG more profitable?

Do analysts recommend NRIX or MDXG?

Which has better earnings & valuation, NRIX or MDXG?

Does the media prefer NRIX or MDXG?

Do insiders & institutionals hold more shares of NRIX or MDXG?

Which has more volatility and risk, NRIX or MDXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools